Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

3

Portfolio Exits

1

About Terry McGuire

Terry McGuire Headquarters Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Terry McGuire News

Creator of breakthrough coronavirus technology to receive inaugural McGuire Prize

May 2, 2022

Creator of breakthrough coronavirus technology to receive inaugural McGuire Prize Dartmouth has announced that the inaugural McGuire Family Prize for Societal Impact will be presented to Jason McLellan, a structural biologist whose groundbreaking coronavirus research conducted at the Geisel School of Medicine laid the foundation for COVID-19 vaccines that have saved countless lives. Dartmouth has announced that the inaugural McGuire Family Prize for Societal Impact will be presented to Jason McLellan, a structural biologist whose groundbreaking coronavirus research conducted at the Geisel School of Medicine laid the foundation for COVID-19 vaccines that have saved countless lives. McLellan, a former assistant professor at the Geisel School, is now the Robert A. Welch Chair in Chemistry at the University of Texas at Austin. He will receive the award at a ceremony Friday, May 13, during the Dartmouth Innovation and Technology Festival and the grand opening of the West End District. Carolyn Carr McGuire TU’83 and Terry McGuire TH’82 established the $100,000 prize as part of The Call to Lead campaign to honor members of the Dartmouth community who have significantly benefited humankind, society, or the environment. Eligible areas of impact encompass a range of achievements, including fundamental science, stewardship of natural resources, and societal leadership. The prize winner is determined by a selection committee comprised of Dartmouth faculty and staff. “We received many outstanding nominations for this prize,” says Eric Fossum, the John H. Krehbiel Sr. Professor for Emerging Technologies and chair of the selection committee. “However, given how COVID-19 has touched each of us in some way, Dr. McLellan’s research defines societal impact in breadth and depth.” McLellan says he is honored to receive the McGuire Family Prize, especially as it’s coming from former colleagues at Dartmouth, “where I started my lab and where I was given the opportunity to be an independent investigator. “Improving people’s lives is exactly what I hoped to do by going into science and particularly working in vaccine development,” he says. “You hope that you can contribute to maybe one major vaccine during your entire career. To be able to contribute to these coronavirus vaccines, which have been given to so many people to blunt a hopefully once-in-a-century pandemic, is incredible.” McLellan and his team at the Geisel School developed the vaccine technology that is the basis for many COVID-19 vaccines used across the planet, including those manufactured by Pfizer, Moderna, and Johnson & Johnson. Coronaviruses have a key protein on their surface, the spike protein, that changes shape before and after infecting a cell. Initially studying the SARS and MERS coronaviruses, McLellan and his postdoctoral researcher Nianshuang Wang developed the means to genetically modify the gene sequence that encodes the protein, essentially locking the structure in place, which allows vaccine antibodies to be more effective. McLellan and Wang moved to UT Austin in 2018. In early 2020, as the COVID-19 pandemic first broke out in Wuhan, McLellan, Wang, and Dartmouth graduate student Daniel Wrapp applied the spike protein-stabilizing technology developed at Geisel to a newly identified virus, SARS-CoV-2, and shared the results of their research with collaborators at the National Institutes of Health. This version of the spike protein was used in the first U.S. COVID-19 vaccine trials and by other vaccine manufacturers in the months that followed. More than five billion people worldwide have received at least one dose of a COVID-19 vaccine, with a large percentage of them receiving vaccines that use the stabilized spike protein technology. Terry McGuire says McLellan represents the leadership, determination, and initiative that he and his wife intended to honor when they established the prize, which emphasizes broad impact and the number of people whose lives are improved. “The prize recognizes talented people who aren’t daunted by the size of a problem, but instead realize that if they are willing to take on and solve a major challenge of our time, they can have a huge impact, often measured in millions of lives touched,” says Terry McGuire. Carolyn McGuire adds, “It also recognizes the important role collaboration often plays in the process, leveraging that impact.” Dartmouth President Philip J. Hanlon ’77 thanked the McGuires for establishing a prize that honors individuals who exemplify values that are at the core of the Dartmouth ethos. “The McGuire Family Prize recognizes those who are dedicated to making a difference. There could be no better example of what it means for a scientist to answer the call to lead. I hope every student on our campus today and everyone in our community are inspired by the example of Dr. McLellan,” says President Hanlon. McLellan emphasizes that tens of thousands of people contributed to the success of the coronavirus vaccines: scientists from academia, government, and industry; manufacturers; volunteers in clinical trials; and health care workers. “The collective will of tens of thousands of people creating, testing, and delivering the vaccines is something for humanity to celebrate,” he says. The Dartmouth Innovation and Technology Festival, May 12–14, is open to the entire Dartmouth community, residents of the Upper Valley, and anyone curious about the power of technology to advance scholarship in all disciplines. The weekend’s slate of activities will include presentations and panel discussions on topics such as artificial intelligence, health care, transportation, and cryptocurrency; makerspace demonstrations; interactive learning experiences; and family-friendly activities, including a community picnic and Friday evening light show. Registration for the weekend is free and encouraged.

Terry McGuire Investments

3 Investments

Terry McGuire has made 3 investments. Their latest investment was in Icelandic Provisions as part of their Series B on January 1, 2017.

CBI Logo

Terry McGuire Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/24/2017

Series B

Icelandic Provisions

$9.14M

No

1

12/21/2015

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/18/2013

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/24/2017

12/21/2015

12/18/2013

Round

Series B

Series A

Seed VC

Company

Icelandic Provisions

Subscribe to see more

Subscribe to see more

Amount

$9.14M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

Terry McGuire Portfolio Exits

1 Portfolio Exit

Terry McGuire has 1 portfolio exit. Their latest portfolio exit was pymetrics on August 11, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/11/2022

Acquired

$99M

5

Date

8/11/2022

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

5

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.